Is targeting micrornas the philosopher’s stone for vascular disease?

Current Vascular Pharmacology

Volumn 14, Issue 1, 2016, Pages 88-97

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Antisense oligonucleotides; Cardiac disease; Gene expression; MicroRNA (miR); MiR mimicking; MiR spongeserasers decoys; Silencing; Vascular disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; MICRORNA 1; MICRORNA 100; MICRORNA 10A; MICRORNA 122; MICRORNA 126; MICRORNA 127; MICRORNA 133A; MICRORNA 145; MICRORNA 146A; MICRORNA 15B; MICRORNA 16; MICRORNA 195; MICRORNA 208A; MICRORNA 20B; MICRORNA 21; MICRORNA 25; MICRORNA 26B; MICRORNA 27B; MICRORNA 320; MICRORNA 33; MICRORNA 335; MICRORNA 363; MICRORNA 92A; MICRORNA 99A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE COURSE; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; LIPID METABOLISM; MIRNA MASKING; MIRNA SPONGE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); POSTTRANSCRIPTIONAL GENE SILENCING; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART DISEASES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR DISEASES;

ANIMALS; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICRORNAS; RENIN-ANGIOTENSIN SYSTEM; VASCULAR DISEASES;

EID: 84949870464     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161113666150401101603     Document Type: Article

References (131)

1. Xu T, Li L, Huang C, Li X, et al. MicroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy. Expert OpinTher Targets 2014; 18: 153-8.
2. Ferreira DM, Simão AL, Rodrigues CM, et al. Revisiting the Metabolic Syndrome and Paving the Way for microRNAs in Non-Alcoholic Fatty Liver Disease. FEBS J 2014; 281: 2503-24.
3. Leung A, Natarajan R. Noncoding RNAs in vascular disease. Curr Opin Cardiol 2014; 29: 199-206.
4. Meng QL, Liu F, Yang XY, et al. Identification of latent tuberculosis infection-related microRNAs in human U937 macrophages expressing Mycobacterium tuberculosis Hsp16.3. BMC Microbiol 2014; 14: 37.
5. Singaravelu R, Russell RS, Tyrrell DL, et al. Hepatitis C virus and microRNAs: miRed in a host of possibilities. Curr Opin Virol 2014; 7C: 1-10.
6. Tessitore A, Cicciarelli G, Del Vecchio F, et al. MicroRNAs in the DNA Damage/Repair Network and Cancer. Int J Genomics 2014; 2014: 820248.
7. Caroli A, Cardillo MT, Galea R, Biasucci LM. Potential therapeutic role of microRNAs in ischemic heart disease. J Cardiol 2013; 61: 315-20.
8. Small EM, Frost RJ, Olson EN. MicroRNAs Add a New Dimension to Cardiovascular Disease Circulation 2010; 121: 1022-32.
9. Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005; 33: 2697-706.
10. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-9.
11. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the microprocessor complex. Nature 2004; 432: 231-5.
12. Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432: 235-40.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
14. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004; 303: 95-8.
15. Jamaluddin MS, Weakley SM, Zhang L, et al. miRNAs: roles and clinical applications in vascular disease. Expert Rev Mol Diagn 2011; 11: 79-89.
16. Bronze-da-Rocha E. MicroRNAs Expression Profiles in Cardiovascular Diseases. Biomed Res Int 2014; 2014: 985408.
17. Guo L, Lu Z. The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One 2010; 5: e11387.
18. Hartmann D, Thum T. MicroRNAs and vascular (dys)function. Vascul Pharmacol 2011; 55: 92-105.
19. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79: 581-8.
20. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol 2010; 20: R858-61.
21. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010; 16: 2043-50.
22. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011; 18: 1104-10.
23. Xiao J, Yang B, Lin H, et al. Novel approaches for gene specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 2007; 212: 285-92.
24. Chen T, Li Z, Tu J, et al. MicroRNA-29a regulates proinflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells. FEBS Lett 2011; 585: 657-63.
25. Gill SL, O'Neill H, McCoy RJ, et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model. Technol Health Care 2014; 22: 37-51.
26. Zhao H, Wang J, Gao L, et al. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke 2013; 44: 1706-13.
27. Ramirez CMI, Dávalos A, Goedeke L, et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 2011; 31: 2707-14.
28. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79: 581-8.
29. Zhang M, Wu JF, Chen WJ, et al. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis 2014; 234: 54-64.
30. Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570-3.
31. Rotllan N, Ramírez CM, Aryal B, et al. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/-mice--brief report. Arterioscler Thromb Vasc Biol 2013; 33: 1973-7.
32. Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014; 11: 72-4.
33. Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin-and dietinduced hepatotoxicity. EMBO Mol Med 2012; 4: 882-95.
34. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438: 685-9.
35. Miyaaki H, Ichikawa T, Kamo Y, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014; 34: e302-e307.
36. Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-9.
37. Athyros VG, Katsiki N, Karagiannis A. Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease. Expert Opin Ther Targets 2013; 17: 861-2.
38. Pan Q, Tilanus HW, Janssen HL, van der Laan LJ. Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert Opin Biol Ther 2009; 9: 713-24.
39. Torella D, Iaconetti C, Catalucci D, et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res 2011; 109: 880-93.
40. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
41. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101: 1225-36.
42. Yang LX, Liu G, Zhu GF, et al. MicroRNA-155 inhibits angiotensin II-induced vascular smooth muscle cell proliferation. J Renin Angiotensin Aldosterone Syst 2014; 15: 109-16.
43. Wu WH, Hu CP, Chen XP, et al. MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension. Am J Hypertens 2011; 24: 1087-93.
44. Chen M, Ma G, Yue Y, et al. Downregulation of the miR-30 family microRNAs contributes to endoplasmic reticulum stress in cardiac muscle and vascular smooth muscle cells. Int J Cardiol 2014; 173: 65-73.
45. Ma X, Ma C, Zheng X. MicroRNA-155 in the pathogenesis of atherosclerosis: a conflicting role? Heart Lung Circ 2013; 22: 811-8.
46. Wei Y, Nazari-Jahantigh M, Neth P, et al. MicroRNA-126,-145, and-155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 2013; 33: 449-54.
47. Strum JC, Johnson JH, Ward J, et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol 2009; 23: 1876-84.
48. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84.
49. Lumeng CN, Del Proposto JB, Westcott DJ, et al. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008; 57: 3239-46.
50. Son Dj, Kumar S, Takabe W, et al. The atypical mechanosenstitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 2013; 4: 3000.
51. Wu W, Xiao H, Laguna-Fernandez A, et al. Flow-dependent regulation of kruppel-like factor 2 is mediated by microRNA-92a. Circulation 2011; 124: 633-41.
52. Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014; 114: 434-43.
53. de Winther MP, Lutgens E. MiR-92a: at the heart of lipid-driven endothelial dysfunction. Circ Res 2014; 114: 399-401.
54. Chiu JJ, Usami S, Chien S. Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann Med 2009; 41: 19-28.
55. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011; 91: 327-87.
56. Chien S. Role of shear stress direction in endothelial mechanotransduction. Mol Cell Biomech 2008; 5: 1-8.
57. Chien S. Effects of disturbed flow on endothelial cells. Ann Biomed Eng 2008; 36: 554-62.
58. Marin T, Gongol B, Chen Z, et al. Mechanosensitive microRNAsrole in endothelial responses to shear stress and redox state. Free Radic Biol Med 2013; 64: 61-8.
59. Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res 2007; 100:1686-1695.
60. Nayak L, Lin Z, Jain MK. ‘Go with the flow’-How Krüppel-like factor 2 regulates the vasoprotective effects of shear stress. Antioxid Redox Signal 2011; 15: 1449-61.
61. Wu W, Xiao H, Laguna-Fernandez A, et al. Flow-Dependent Regulation of Kruppel-Like Factor 2 Is Mediated by MicroRNA-92a. Circulation 2011; 124: 633-41.
62. Neth P, Nazari-Jahantigh M, Schober A, et al. MicroRNAs in flowdependent vascular remodelling. Cardiovasc Res 2013; 99: 294-303.
63. Sun X, He S, Wara AK, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-_B activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014; 114: 32-40.
64. Sun X, Icli B, Wara AK, et al. MicroRNA-181b regulates NF-_Bmediated vascular inflammation. J Clin Invest 2012; 122: 1973-90.
65. Raitoharju E, Oksala N, Lehtimäki T. MicroRNAs in the atherosclerotic plaque. Clin Chem 2013; 59: 1708-21.
66. Raitoharju E, Lyytikäinen LP, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011; 219: 211-7.
67. Du Y, Gao C, Liu Z, et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol 2012; 32: 2580-8.
68. Nasir K, Rivera JJ, Yoon YE, et al. Variation in atherosclerotic plaque composition according to increasing coronary artery calcium scores on computed tomography angiography. Int J Cardiovasc Imaging 2010; 26: 923-32.
69. Fan X, Wang E, Wang X, et al. MicroRNA-21 is a unique signature associated with coronary plaque instability in humans by regulating matrix metalloproteinase-9 via reversion-inducing cysteinerich protein with Kazal motifs. Exp Mol Pathol 2014; 96: 242-9.
70. Lehrke MI, Greif M, Broedl UC. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol 2009; 8: 50.
71. Santovito D, Mandolini C, Marcantonio P, et al. Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients. Expert Opin Ther Targets 2013; 17: 217-23.
72. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
73. Zeller T, Keller T, Ojeda F, et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J 2014; 35: 2106-14.
74. Li C, Fang Z, Jiang T, et al. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. BMC Med Genomics 2013; 6: 16.
75. Zhu GF, Yang LX, Guo RW, et al. microRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score. Coron Artery Dis 2014; 25: 304-10.
76. Zhu H, Fan GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res 2012; 94: 284-92.
77. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014; 124: 2136-46.
78. Huang S, Chen M, Li L, et al. Circulating microRNAs and the occurrence of acute myocardial infarction in chinese populations. Circ Cardiovasc Genet 2014; 7: 189-98.
79. Xiao J, Shen B, Li J, et al. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. Int J Clin Exp Med 2014; 7: 136-41.
80. Olivieri F, Antonicelli R, Spazzafumo L, et al. Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. Int J Cardiol 2014; 172: e276-8.
81. Li Q, Xie J, Li R, et al. Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. J Cell Mol Med 2014; 18: 919-28.
82. Qin Y, Yu Y, Dong H, Bian X, Guo X, Dong S. MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis. Int J Med Sci 2012; 9: 413-23.
83. Yang Q, Yang K, Li A. microRNA-21 protects against ischemia-reperfusion and hypoxia- reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism. Mol Med Rep 2014; 9:2213-20.
84. Cipollone F, Felicioni L, Sarzani R, et al. A unique microRNA signature associated with plaque instability in humans. Stroke 2011; 42: 2556-63.
85. Tsai PC, Liao YC, Wang YS, et al. Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. J Vasc Res 2013; 50: 346-54.
86. Wang Y, Zhang Y, Huang J, et al. Increase of circulating miR-223 and insulin-like growth factor-1 is associated with the pathogenesis of acute ischemic stroke in patients. BMC Neurol 2014; 14: 77.
87. Jeon YJ, Kim OJ, Kim SY, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol 2013; 33: 420-30.
88. Stather PW, Sylvius N, Wild JB, et al. Differential MicroRNA Expression Profiles in Peripheral Arterial Disease. Circ Cardiovasc Genet 2013; 6: 490-7.
89. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-3.
90. Hinkel R, Penzkofer D, Zühlke S, et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013; 128: 1066-75.
91. Grundmann S, Hans FP, Kinniry S, et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation 2011; 123: 999-1009.
92. Wang M, Li W, Chang GQ, et al. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol 2011; 31: 2044-53.
93. Li T, Cao H, Zhuang J, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta 2011; 412: 66-70.
94. Caporali A, Meloni M, Vollenkle C, et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011; 123: 282-91.
95. Minami Y, Satoh M, Maesawa C, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest 2009; 39: 359-67.
96. Tabuchi T, Satoh M, Itoh T, et al. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 2012; 123: 161-71.
97. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNAs-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-3.
98. Ho PC, Chang KC, Chuang YS, et al. Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production. FASEB J 2011; 25: 1758-66.
99. Minami Y, Satoh M, Maesawa C, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest 2009; 39: 359-67.
100. Eskildsen TV, Jeppesen PL, Schneider M, et al. Angiotensin II Regulates microRNA-132/-212 in Hypertensive Rats and Humans. Int J Mol Sci 2013; 14: 11190-207.
101. Nossent AY, Hansen JL, Doggen C, et al. SNPs in microRNA binding sites in 3_-UTRs of RAAS genes influences arterial blood pressure and risk of myocardial infarction. Am J Hypertens 2011; 24: 999-1006.
102. Weber M, Baker MB, Patel RS, et al. MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract 2011; 2011: 532915.
103. Deiuliis J, Mihai G, Zhang J, et al. Renin-sensitive microRNAs correlate with atherosclerosis plaque progression. J Hum Hypertens 2014; 28: 251-8.
104. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18: 781-8.
105. Grothusen C, Bley S, Selle T, et al. Combined effects of HMGCoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005; 182: 57-69.
106. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Cur Pharmac Des 2014; 20: 6299-305.
107. Takahashi Y, Satoh M, Minami Y, et al. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 2010; 119: 395-405.
108. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-9.
109. Montgomery RL, van Rooij E. Therapeutic advances in MicroRNA targeting. J Cardiovasc Pharmacol 2011; 57: 1-7.
110. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
111. Stenvang J, Lindow M, Kauppinen S. Targeting of microRNAs for therapeutics. Biochem Soc Trans 2008; 36: 1197-200.
112. Elmén J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36: 1153-62.
113. de Jong YP, Jacobson IM. Antisense therapy for hepatitis C virus infection. J Hepatol 2014; 60: 227-8.
114. Köberle V, Waidmann O, Kronenberger B, et al. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. J Viral Hepat 2013; 20: 530-5.
115. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-47.
116. Rayner KJ, Fernandez-Hernando C, Moore KJ. MicroRNAs regulating lipid metabolism in atherogenesis. Thromb Haemost 2012; 107: 642-7.
117. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566-9.
118. Fernández-Hernando C, Moore KJ. MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2011; 31: 2378-82.
119. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404-7.
120. Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012; 110: 71-81.
121. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-8.
122. Kluiver J, Gibcus JH, Hettinga C, et al. Rapid Generation of MicroRNA Sponges for MicroRNA Inhibition. PLoS One 2012; 7: e29275.
123. Papapetrou EP, Korkola JE, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells 2010; 28: 287-96.
124. Dellago H, Preschitz-Kammerhofer B, Terlecki-Zaniewicz L, et al. High levels of oncomiR-21 contribute to the senescence-induced growth arrest in normal human cells and its knock-down increases the replicative lifespan. Aging Cell 2013; 12: 446-58.
125. Sun X, He S, Wara AK, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-_B activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014; 114: 32-40.
126. Gill SL, O'Neill H, McCoy RJ, et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model. Technol Health Care 2014; 22: 37-51.
127. Raimondi L, Amodio N, Di Martino MT, et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget 2014; 5: 3039-54.
128. Prislei S, Martinelli E, Mariani M, et al. MiR-200c and HuR in ovarian cancer. BMC Cancer 2013; 13: 72.
129. Peschansky VJ, Wahlestedt C. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics 2014; 9: 3-12.
130. Athyros VG, Katsiki N, Karagiannis A. microRNAs: potential targets for the treatment of cardiovascular disease. Cur Vasc Pharmacol 2014 [in press]
131. Condorelli G, Latronico MVG, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. JACC 2014; 63: 2177-87.